<DOC>
	<DOC>NCT00638183</DOC>
	<brief_summary>Since Spiriva Inhalation Capsules 18mcg (hereinafter this product) are indicated for treatment of patients with chronic obstructive pulmonary disease (i.e. patients with chronic bronchitis or pulmonary emphysema) and usually intended for long-term use, the present survey is conducted to collect safety and effectiveness information on the use of this product for long period of time in daily clinical settings, and to obtain proper drug use information.</brief_summary>
	<brief_title>Special Survey Long-term Treatment With Tiotropium on COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>1. Patients of Chronic Obstructive Pulmonary Disease 2. Patients were expected to use the product for long period of time 1. Patients with glaucoma 2. Patients with micturition disorder due to prostatic hyperplasia etc. 3. Patients with a history of hypersensitivity to atropine or its derivatives or to any component of this product</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>